Please try another search
Kineta, Inc., formerly Yumanity Therapeutics Inc., is a clinical-stage biotechnology company. The Company is focused on discovering and developing differentiated immunotherapies that address the challenges with current cancer therapy. The Company's immuno-oncology focused PiiONEER Platform aims at developing fully human antibodies to address the major mechanisms of cancer immune resistance, such as immuno-suppression, exhausted T cells and poor tumor immunogenicity. Its pipeline of assets developed through the PiiONEER Platform includes KVA12123, a monoclonal antibody (mAb) immunotherapy targeting V-domain Ig suppressor of T cell activation (VISTA), an anti-CD27 agonist mAb immunotherapy and an anti-CD24 antagonist mAb immunotherapy discovery program. VISTA blocks immunotherapy to address the problem of immunosuppression in the tumor microenvironment. It is developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells in the tumor microenvironment.
| Name | Age | Since | Title |
|---|---|---|---|
| Evan Ya-Wen Yu | - | 2023 | Member of Scientific Advisory Board |
| Myriam Chalabi | - | 2023 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
